MARKET

AGEN

AGEN

Agenus
NASDAQ
2.940
+0.170
+6.14%
After Hours: 2.940 0 0.00% 16:10 02/06 EST
OPEN
2.780
PREV CLOSE
2.770
HIGH
3.010
LOW
2.780
VOLUME
490.21K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
106.26M
P/E (TTM)
-1.4055
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AGEN last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at AGEN last week (0119-0123)?
Weekly Report · 01/26 10:36
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Agenus (AGEN) and Assertio Therapeutics (ASRT)
TipRanks · 01/21 15:30
Looking Into Agenus Inc's Recent Short Interest
Benzinga · 01/21 15:00
Agenus Expands Global Medical Affairs Infrastructure And Early-Access Support Capabilities In Response To Increasing Physician-Initiated Interest Regarding Authorized Access To BOT+BAL
Benzinga · 01/21 12:34
Agenus Expands Medical Affairs Infrastructure Amid Rising Demand for Botensilimab Access
Reuters · 01/21 12:30
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
Barchart · 01/21 06:30
Agenus Launches Stakeholder Webcast Showcasing Global Momentum for BOT+BAL Program
Reuters · 01/20 23:24
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.